Paid Clinical Trials for Blood Disorders, Multiple Myeloma

Paid Clinical Trials and Focus Groups by Category

Find Paid Clinical Trials

Find Paid Clinical Trials All Categories ... by Medical Condition » ... Blood Disorders » ... Multiple Myeloma


  • A Phase 2 Study of AZD6244 in Multiple Myeloma

    Condition:   Multiple Myeloma
    Intervention:   Drug: AZD6244 hydrogen sulfate capsules
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Connect™ MM- The Multiple Myeloma Disease Registry

    Condition:   Multiple Myeloma
    Intervention:  
    Sponsor:   Celgene Corporation
    Recruiting - verified March 2010
  • Lenalidomide and High-Dose Melphalan

    Conditions:   Myeloma;   Stem Cell Transplantation
    Interventions:   Drug: Lenalidomide;   Drug: Melphalan
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified March 2010
  • Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant

    Conditions:   Cancer Survivor;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Testicular Germ Cell Tumor
    Interventions:   Genetic: DNA analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: laboratory biomarker analysis
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2010
  • Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   Atypical Chronic Myeloid Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   De Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Myelodysplastic/Myeloproliferative Disease, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma
    Interventions:   Drug: plerixafor;   Biological: filgrastim;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsor:   Fred Hutchinson Cancer Research Center
    Not yet recruiting - verified February 2010
  • Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

    Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: plerixafor;   Biological: filgrastim;   Drug: cyclophosphamide;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsor:   City of Hope Medical Center
    Not yet recruiting - verified February 2010
  • A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

    Condition:   Multiple Myeloma
    Intervention:   Drug: KW-2478 and bortezomib
    Sponsors:   Kyowa Hakko Kirin Pharma, Inc.;   Kyowa Hakko Kirin UK, Ltd.;   Kyowa Hakko Kirin Company, Limited
    Not yet recruiting - verified January 2010
  • Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

    Condition:   Multiple Myeloma
    Interventions:   Drug: lenalidomide;   Drug: melphalan
    Sponsors:   Weill Medical College of Cornell University;   Celgene Corporation
    Recruiting - verified March 2010
  • Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

    Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: bendamustine hydrochloride;   Drug: lenalidomide;   Drug: dexamethasone
    Sponsor:   Mayo Clinic
    Recruiting - verified March 2010
  • Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

    Condition:   Multiple Myeloma
    Interventions:   Drug: carfilzomib, lenalidomide plus dexamethasone;   Drug: carfilzomib, lenalidomide plus dexamethasone
    Sponsors:   University of Michigan Cancer Center;   Onyx Therapeutics, Inc.;   Celgene Corporation
    Recruiting - verified February 2010
  • Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

    Condition:   Multiple Myeloma
    Intervention:   Drug: CEP-18770
    Sponsor:   Cephalon
    Recruiting - verified March 2010
  • Donor Lymphocytes in Preventing and Treating Cytomegalovirus Infection or Adenovirus Infection in Patients Who Have Undergone Umbilical Cord Blood Transplant

    Condition:   Cancer
    Interventions:   Biological: allogeneic CMV/AdV-specific cytotoxic T lymphocytes;   Other: laboratory biomarker analysis
    Sponsors:   Baylor College of Medicine;   National Cancer Institute (NCI)
    Recruiting - verified December 2009
  • Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

    Condition:   Multiple Myeloma
    Interventions:   Drug: Perifosine;   Drug: Perifosine Placebo;   Drug: Bortezomib;   Drug: Dexamethasone
    Sponsors:   Keryx / AOI Pharmaceuticals, Inc.;   Dana-Farber Cancer Institute
    Recruiting - verified March 2010
  • Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

    Conditions:   Multiple Myeloma;   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: plerixafor;   Drug: filgrastim
    Sponsor:   Mayo Clinic
    Recruiting - verified March 2010
  • Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

    Conditions:   Advanced Solid Tumors;   Multiple Myeloma
    Intervention:   Biological: ACE-041
    Sponsor:   Acceleron Pharma, Inc.
    Recruiting - verified February 2010
  • Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Methemoglobinemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm
    Interventions:   Drug: chemotherapy;   Drug: dapsone;   Other: medical chart review;   Procedure: assessment of therapy complications
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2009
  • IMGN901 in Combination With Lenalidomide and Dexamethasone

    Condition:   Multiple Myeloma
    Intervention:   Drug: IMGN901
    Sponsor:   ImmunoGen, Inc.
    Recruiting - verified March 2010
  • Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

    Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplasia;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma;   Myelofibrosis;   Anemia, Aplastic;   Hemoglobinuria, Paroxysmal
    Intervention:   Drug: Basiliximab
    Sponsor:   Indiana University School of Medicine
    Recruiting - verified March 2010
  • Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders

    Conditions:   Leukemia;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   MDS;   Multiple Myeloma
    Interventions:   Drug: EPOCH-F/R;   Drug: FLAG;   Drug: Transplant Preparative Regimen (Flu/Cy/Mes);   Drug: GVHD Prophylaxis (tacrolimus and sirolimus);   Procedure: Double Cord Blood Transplantation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm
    Interventions:   Biological: trivalent influenza vaccine;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
    Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

    Conditions:   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: everolimus;   Drug: panobinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Viral Infection
    Interventions:   Other: cytology specimen collection procedure;   Other: fluorescent antibody technique;   Procedure: assessment of therapy complications
    Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Home Visits or Standard Therapy in Treating Patients Undergoing Donor Stem Cell Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Psychosocial Effects of Cancer and Its Treatment;   Therapy-related Toxicity
    Interventions:   Behavioral: exercise intervention;   Behavioral: telephone-based intervention;   Dietary Supplement: dietary intervention;   Other: educational intervention;   Other: questionnaire administration;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: assessment of therapy complications;   Procedure: peripheral blood stem cell transplantation;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment;   Procedure: standard follow-up care
    Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

    Condition:   Cancer
    Interventions:   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer

    Condition:   Cancer
    Interventions:   Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: medical chart review;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: evaluation of cancer risk factors
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2009
  • Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

    Conditions:   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous Condition
    Interventions:   Dietary Supplement: defined green tea catechin extract;   Genetic: gene expression analysis;   Genetic: protein analysis;   Other: laboratory biomarker analysis
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified February 2010
  • Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma

    Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Biological: anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified February 2010
  • 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Other: 3'-deoxy-3'-[18F]fluorothymidine
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified September 2009
  • A Pharmacokinetic Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

    Condition:   Multiple Myeloma
    Interventions:   Drug: Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection;   Drug: Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)
    Sponsor:   CyDex Pharmaceuticals, Inc.
    Recruiting - verified February 2010
  • Collecting and Storing Blood and Bone Marrow Samples From Patients With Myeloma, Waldenstrom's Macroglobulinemia, Amyloidosis, or Monoclonal Gammopathy of Undetermined Significance

    Conditions:   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous Condition
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

    Condition:   Multiple Myeloma
    Intervention:   Drug: bendamustine as combination therapy with bortezomib
    Sponsor:   Cephalon
    Recruiting - verified March 2010
  • Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

    Condition:   Multiple Myeloma
    Interventions:   Drug: Bendamustine;   Drug: Melphalan;   Drug: Bendamustine;   Drug: Bendamustine;   Drug: Bendamustine;   Drug: Bendamustine
    Sponsor:   Weill Medical College of Cornell University
    Recruiting - verified March 2010
  • Busulfan in Multiple Myeloma

    Condition:   Multiple Myeloma
    Intervention:   Drug: Busulfan
    Sponsors:   University of Utah;   Otsuka Pharmaceutical Development & Commercialization, Inc.
    Recruiting - verified February 2010
  • Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

    Conditions:   Hematopoietic/Lymphoid Cancer;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Multiple Myeloma;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: panobinostat;   Drug: everolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: western blotting
    Sponsor:   Mayo Clinic
    Recruiting - verified March 2010
  • A Study of the Safety and Effectiveness of CNTO 328 When Added to Velcade-Melphalan-Prednisone in Patients With Multiple Myeloma

    Condition:   Multiple Myeloma
    Interventions:   Drug: 328 plus VMP (Part 1, Part 2-Arm A);   Drug: VMP Alone (Part 2-Arm B)
    Sponsor:   Centocor, Inc.
    Recruiting - verified February 2010
  • Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

    Conditions:   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous Condition
    Interventions:   Genetic: cytogenetic analysis;   Genetic: microarray analysis;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant

    Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
    Interventions:   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: polymorphism analysis;   Genetic: proteomic profiling;   Other: flow cytometry;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: biopsy
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified October 2008
  • Collecting and Storing Blood Samples From Patients With Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
    Recruiting - verified August 2008
  • Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant

    Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nausea and Vomiting;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
    Interventions:   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: medical chart review
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Studying Fentanyl in Patients With Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: fentanyl citrate;   Other: pharmacological study
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

    Conditions:   Breast Cancer;   Hypercalcemia of Malignancy;   Colon Cancer;   Endocrine Cancer;   Head and Neck Cancer;   Kidney Cancer;   Lung Cancer;   Lymphoma;   Metastatic Cancer;   Multiple Myeloma;   Parathyroid Neoplasms;   Renal Cancer;   Thyroid Cancer;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Non-small Cell Lung Cancer
    Intervention:   Drug: denosumab
    Sponsor:   Amgen
    Recruiting - verified March 2010
  • Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy

    Conditions:   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonneoplastic Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: sunitinib malate;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
    Sponsors:   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant

    Condition:   Cancer
    Interventions:   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis;   Procedure: allogeneic bone marrow transplantation
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

    Condition:   Cancer
    Interventions:   Other: immunological diagnostic method;   Other: physiologic testing
    Sponsors:   Wake Forest University;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

    Condition:   Advanced Cancer, Various, NOS
    Interventions:   Drug: BMS-833923;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Bortezomib
    Sponsors:   Bristol-Myers Squibb;   Exelixis
    Recruiting - verified December 2009
  • Iron Overload in Patients Undergoing Donor Stem Cell Transplant

    Condition:   Cancer
    Interventions:   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: assessment of therapy complications;   Procedure: magnetic resonance imaging
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

    Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Procedure: assessment of therapy complications
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

    Conditions:   Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
    Intervention:   Drug: zoledronic acid
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Fludarabine, Melphalan, Total-Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

    Conditions:   Chronic Myeloproliferative Disorders;   Fanconi Anemia;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria
    Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant

    Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
    Interventions:   Other: educational intervention;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: survey administration;   Procedure: psychosocial assessment and care;   Procedure: stress management therapy;   Procedure: support group therapy
    Sponsors:   University of Colorado, Denver;   National Cancer Institute (NCI)
    Recruiting - verified January 2009
  • Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Therapy-related Toxicity
    Interventions:   Biological: immunosuppressive therapy;   Other: immunological diagnostic method;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

    Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Myelodysplastic Syndrome;   Philadelphia Chromosome-negative CML;   Myeloid Metaplasia;   Myelofibrosis;   Advanced Polycythemia;   Non-Hodgkins Lymphoma
    Intervention:   Drug: TAK-901
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified March 2010
  • Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: intensity-modulated radiation therapy;   Radiation: tomotherapy;   Radiation: total marrow irradiation;   Radiation: total nodal irradiation
    Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Stem Cell Transplant Cope With Late Complications

    Condition:   Cancer
    Interventions:   Other: internet-based intervention;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: fatigue assessment and management;   Procedure: management of therapy complications;   Procedure: psychosocial assessment and care
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Natural Killer Cells and Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: natural killer cell therapy;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Early Administration of Antithymocyte Globulin Followed By Cyclophosphamide, Busulfan, and Fludarabine Before a Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Kidney Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Genetic: polymerase chain reaction;   Other: pharmacological study;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsor:   Blood and Marrow Transplant Group of Georgia
    Recruiting - verified June 2009
  • Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

    Condition:   Multiple Myeloma
    Intervention:   Drug: BIW-8962
    Sponsor:   Kyowa Hakko Kirin Pharma, Inc.
    Recruiting - verified January 2009
  • Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

    Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: dexamethasone;   Drug: lenalidomide;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: staining method;   Procedure: bone marrow aspiration
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified February 2010
  • Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers

    Conditions:   Chronic Myeloproliferative Disorders;   Depression;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Psychosocial Effects of Cancer and Its Treatment;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Other: medical chart review;   Other: questionnaire administration;   Procedure: psychosocial assessment and care
    Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
    Recruiting - verified August 2008
  • Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

    Condition:   Cancer
    Interventions:   Biological: cytomegalovirus IE-1-specific cytotoxic T lymphocytes;   Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes;   Biological: therapeutic allogeneic lymphocytes;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunological diagnostic method;   Other: laboratory biomarker analysis
    Sponsors:   Milton S. Hershey Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2008
  • Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

    Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Lymphoma;   Multiple Myeloma;   Leukemia, Myelomonocytic, Chronic
    Intervention:   Drug: azacitidine
    Sponsor:   Celgene Corporation
    Recruiting - verified March 2010
  • Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Drug: cyclosporine ophthalmic emulsion;   Other: placebo
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Trial Of Double Umbilical Cord Blood Transplantation

    Condition:   Hematological Malignancies
    Interventions:   Procedure: full intensity, double umbilical cord, stem cell transplant;   Drug: Flu/Bu4 conditioning regimen;   Radiation: Total Lymphoid Irradiation (TLI);   Drug: Graft versus Host Disease prevention (GVHD prophylaxis)
    Sponsor:   University of Michigan Cancer Center
    Recruiting - verified February 2010
  • Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Other: educational intervention
    Sponsors:   Fox Chase Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Pain;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: methadone hydrochloride;   Drug: morphine sulfate;   Drug: oxycodone hydrochloride
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma (Study P05538AM3)

    Conditions:   Neoplasms;   Lymphoma;   Multiple Myeloma
    Interventions:   Drug: SCH 900105;   Drug: SCH 900105;   Drug: SCH 900105;   Drug: Erlotinib
    Sponsors:   Schering-Plough;   AVEO Pharmaceuticals, Inc.
    Recruiting - verified February 2010
  • Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • American Ginseng in Treating Patients With Fatigue Caused by Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Fatigue;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Dietary Supplement: American ginseng;   Other: placebo
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Study of MLN8237 in Patients With Advanced Hematological Malignancies

    Conditions:   B-cell Follicular Lymphoma;   B-cell Marginal Zone Lymphoma;   Diffuse Large B-cell Lymphoma;   B-cell Mantle Cell Lymphoma;   B-cell Small Lymphocytic Lymphoma (SLL);   B-Cell Chronic Lymphocytic Leukemia (B-CLL);   Multiple Myeloma;   Waldenstrom's Macroglobulinemia
    Intervention:   Drug: MLN8237
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified February 2010
  • Imatinib Mesylate in Treating Patients With Sclerodermatous Chronic Graft-Versus-Host Disease

    Condition:   Cancer
    Interventions:   Drug: imatinib mesylate;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: confocal microscopy;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: biopsy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2010
  • Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: rituximab;   Drug: busulfan;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Radiation: total-body irradiation
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified January 2010
  • Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

    Conditions:   Adrenocortical Carcinoma;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Sarcoma;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Biological: cixutumumab;   Drug: temsirolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2010
  • Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Pain;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Other: questionnaire administration;   Procedure: acupressure therapy;   Procedure: biopsy;   Procedure: bone marrow aspiration;   Procedure: pain therapy
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Pain;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Other: educational intervention;   Other: medical chart review;   Other: questionnaire administration;   Procedure: pain therapy;   Procedure: quality-of-life assessment
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified October 2009
  • Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

    Conditions:   Multiple Myeloma;   Primary Amyloidosis
    Interventions:   Drug: Melphalan;   Procedure: Stem Cell Infusion;   Behavioral: Questionnaires;   Drug: Granulocyte-colony stimulating factor (G-CSF);   Procedure: Apheresis
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified March 2010
  • Montelukast in Treating Patients With Bronchiolitis Obliterans After Stem Cell Transplant

    Condition:   Cancer
    Interventions:   Drug: montelukast sodium;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2008
  • Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

    Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition
    Interventions:   Biological: alemtuzumab;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsor:   Baylor College of Medicine
    Recruiting - verified June 2009
  • Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

    Condition:   Cancer
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: rituximab;   Drug: clofarabine;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
    Recruiting - verified October 2008
  • Stem Cell Transplantation To Treat High Risk Lymphoid Diseases With Reduced Toxicity Myeloablative Conditioning Regimen

    Conditions:   Multiple Myeloma;   Plasma Cell Leukemia;   Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Fludarabine/Busulfan x 4 days;   Procedure: stem cell transplant
    Sponsors:   University of Michigan Cancer Center;   PDL BioPharma, Inc.
    Recruiting - verified March 2010
  • T Lymphocytes in Treating Patients Undergoing a Donor Bone Marrow Transplant

    Condition:   Cancer
    Interventions:   Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes;   Genetic: polymerase chain reaction;   Other: immunological diagnostic method;   Procedure: adjuvant therapy
    Sponsor:   Baylor College of Medicine
    Recruiting - verified June 2009
  • Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

    Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: lenalidomide;   Drug: melphalan;   Drug: prednisone;   Drug: thalidomide
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Secondary Myelofibrosis;   Small Intestine Cancer
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

    Condition:   Multiple Myeloma
    Interventions:   Drug: Dasatinib;   Drug: Bortezomib;   Drug: Dexamethasone
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified January 2010
  • Dasatinib in Combination With Revlimid (and Dexamethasone)

    Condition:   Multiple Myeloma
    Intervention:   Drug: Dasatinib + Lenalidomide + Dexamethasone
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified January 2010
  • An Investigational Drug, PD 0332991, Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

    Condition:   Multiple Myeloma
    Interventions:   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: PD 0332991
    Sponsor:   Pfizer
    Recruiting - verified March 2010
  • High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

    Conditions:   Childhood Germ Cell Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Neuroblastoma;   Testicular Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Drug: busulfan;   Drug: carboplatin;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: melphalan;   Drug: thiotepa;   Radiation: total-body irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

    Condition:   Cancer
    Interventions:   Drug: fentanyl sublingual spray;   Other: questionnaire administration
    Sponsor:   Insys Therapeutics Inc
    Recruiting - verified October 2008
  • Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

    Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies

    Conditions:   Cancer;   Lymphoma
    Intervention:   Drug: XL228
    Sponsor:   Exelixis
    Recruiting - verified March 2010
  • Chemotherapy, Donor Stem Cell Transplant, and Graft-Versus-Host Disease Prevention in Treating Patients With Advanced Hematologic Cancer or Other Disease

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: alemtuzumab;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: prednisone;   Drug: sirolimus;   Drug: tacrolimus;   Drug: vincristine sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study

    Condition:   Bone Cancer
    Intervention:   Drug: Dalteparin
    Sponsors:   M.D. Anderson Cancer Center;   Pfizer
    Recruiting - verified March 2010
  • Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: rasburicase;   Drug: sirolimus;   Drug: tacrolimus;   Other: flow cytometry;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsor:   Massachusetts General Hospital
    Recruiting - verified April 2008
  • Randomized Phase 3b Study in Previously Untreated Multiple Myeloma Patients: VELCADE,Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone

    Condition:   Multiple Myeloma
    Interventions:   Drug: bortezomib, thalidomide, and dexamethasone (VTD);   Drug: bortezomib and dexamethasone (VD);   Drug: bortezomib, melphalan and prednisone (VMP)
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified February 2010
  • Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

    Condition:   Cancer
    Interventions:   Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunologic technique;   Other: laboratory biomarker analysis
    Sponsor:   Milton S. Hershey Medical Center
    Recruiting - verified October 2007
  • Beclomethasone in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Drug: beclomethasone dipropionate;   Drug: methotrexate;   Drug: tacrolimus;   Other: placebo
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

    Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Biological: filgrastim;   Drug: dexamethasone;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified February 2010
  • Long-Term Follow Up Study for AMD3100 Patients

    Condition:   Myeloma
    Intervention:   Other: Telephone Questionnaire
    Sponsors:   M.D. Anderson Cancer Center;   AnorMED
    Recruiting - verified March 2010
  • Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: graft-versus-tumor induction therapy;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   Wake Forest University;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: alemtuzumab;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2008
  • Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Biological: sargramostim;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2008
  • Education Sessions for Young Relative Stem Cell Donors

    Condition:   Cancer
    Interventions:   Other: counseling intervention;   Other: educational intervention;   Procedure: psychosocial assessment and care
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2008
  • VEGF Trap in Treating Patients With Stage II or Stage III Multiple Myeloma That Has Relapsed or Not Responded to Previous Treatment

    Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Biological: aflibercept;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Weill Medical College of Cornell University;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Cellular Therapy With Cord Blood Cells

    Conditions:   Multiple Myeloma;   Leukemia;   Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Procedure: Umbilical Cord Blood;   Drug: Rituximab;   Other: Peripheral Blood Stem Cell Infusion
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified March 2010
  • Bevacizumab and Bortezomib in Patients With Advanced Malignancy

    Conditions:   Advanced Malignancy;   Lymphoma;   Myeloma;   Solid Tumors
    Interventions:   Drug: Bevacizumab;   Drug: Bortezomib
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified March 2010
  • Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous Condition;   Secondary Myelofibrosis;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: pemetrexed disodium;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   Robert H. Lurie Cancer Center
    Recruiting - verified July 2009
  • Lithium in Treating Patients With Acute Intestinal Graft-Versus-Host Disease After Donor Stem Cell Transplant

    Condition:   Cancer
    Intervention:   Drug: lithium carbonate
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Secondary Myelofibrosis;   Small Intestine Cancer
    Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified June 2009
  • BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

    Condition:   Multiple Myeloma
    Intervention:   Drug: BB-10901
    Sponsor:   ImmunoGen, Inc.
    Recruiting - verified March 2010
  • Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Umbilical Cord Blood Stem Cell Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer and Other Diseases

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2009
  • Clinical Evaluations and Laboratory Studies in Patients With Chronic Graft-Versus-Host Disease Who Have Undergone a Previous Donor Stem Cell Transplant

    Condition:   Cancer
    Interventions:   Other: laboratory biomarker analysis;   Other: physiologic testing;   Procedure: biopsy;   Procedure: management of therapy complications
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2006
  • Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

    Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
    Intervention:   Drug: moxifloxacin hydrochloride
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
    Recruiting - verified October 2008
  • Combination Chemotherapy and Radiation Therapy Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

    Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: CD4+CD25+ regulatory T cells;   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
    Recruiting - verified September 2009
  • Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unusual Cancers of Childhood
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified June 2007
  • Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: graft-versus-tumor induction therapy;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
    Sponsor:   James P. Wilmot Cancer Center
    Recruiting - verified June 2007
  • Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition
    Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified January 2009
  • Autologous Transplant for Multiple Myeloma

    Condition:   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: cyclophosphamide, melphalan;   Drug: Thalidomide and Dexamethasone
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2010
  • Stem Cell Transplant for Hematological Malignancy

    Conditions:   Leukemia, Myeloid, Chronic;   AML;   Leukemia, Lymphocytic, Acute;   MDS;   Leukemia, Lymphocytic, Chronic;   JMML;   Hodgkin's Disease;   Non-Hodgkin's Lymphoma;   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Busulfan
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2010
  • Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Radiation: radiation therapy
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Combination Chemotherapy, Tacrolimus, and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant For Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: bone marrow ablation with stem cell support
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Alemtuzumab, Fludarabine, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: alemtuzumab;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
    Intervention:   Drug: fenretinide
    Sponsors:   California Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Pentostatin and Donor White Blood Cells in Preventing Graft Rejection in Cancer Patients Who Have Undergone Donor Stem Cell Transplantation

    Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Sarcoma;   Testicular Germ Cell Tumor
    Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: pentostatin
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: graft-versus-tumor induction therapy;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2009
  • T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: filgrastim;   Biological: graft-versus-tumor induction therapy;   Biological: rituximab;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: prednisone;   Drug: vincristine sulfate;   Procedure: peripheral blood stem cell transplantation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Sirolimus in Preventing Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: sirolimus
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2007
  • Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Allogeneic Transplantation

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Sarcoma;   Testicular Germ Cell Tumor
    Intervention:   Biological: therapeutic allogeneic lymphocytes
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2009
  • High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

    Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: melphalan;   Drug: thalidomide;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: umbilical cord blood transplantation;   Drug: methylprednisolone
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Biological: sargramostim;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Screening Individuals and Families at High Risk for Hematologic Cancers

    Conditions:   Brain and Central Nervous System Tumors;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Genetic: genetic linkage analysis;   Genetic: microarray analysis;   Other: counseling intervention;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: evaluation of cancer risk factors
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2007
  • Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma

    Conditions:   Leukemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Genetic: chromosomal translocation analysis;   Genetic: cytogenetic analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation

    Conditions:   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Oral Complications;   Ovarian Cancer;   Pain;   Sarcoma
    Interventions:   Procedure: management of therapy complications;   Procedure: pain therapy
    Sponsor:   Medical College of Wisconsin
    Recruiting - verified June 2009
  • Chemotherapy and Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Disease or Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: anti-thymocyte globulin;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Procedure: peripheral blood stem cell transplantation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified June 2009

Main Menu

Find Clinical Trials